A nationwide study aimed to identify the extended-spectrum ␤-lactamases (ESBLs), metallo-␤-lactamases (MBLs), and extended-spectrum oxacillinases (ES-OXAs) in a French collection of 140 clinical Pseudomonas aeruginosa isolates highly resistant to ceftazidime. Six ESBLs (PER-1, n ‫؍‬ 3; SHV-2a, n ‫؍‬ 2; VEB-1a, n ‫؍‬ 1), four MBLs (VIM-2, n ‫؍‬ 3; IMP-18, n ‫؍‬ 1), and five ES-OXAs (OXA-19, n ‫؍‬ 4; OXA-28, n ‫؍‬ 1) were identified in 13 isolates (9.3% of the collection). The prevalence of these enzymes is still low in French clinical P. aeruginosa isolates but deserves to be closely monitored.
Pseudomonas aeruginosa could potentially become resistant to any of the antibiotics used to treat Gram-negative nosocomial infections. The development of resistance to ␤-lactams in this opportunistic pathogen results from mutations leading to stable overexpression of intrinsic cephalosporinase AmpC, overproduction of efflux systems, reduced permeability, acquisition of transferable genes coding for a variety of secondary ␤-lactamases, or a combination of these mechanisms (21) . A growing number of Ambler class A extended-spectrum ␤-lactamases (ESBLs), class B carbapenemases (metallo-␤-lactamases [MBLs]), and class D extended-spectrum oxacillinases (ES-OXAs) have been reported in clinical strains of P. aeruginosa (14, 18, 19, 34, 40) . The present multicenter study gave a snapshot of these acquired enzymes in a French collection of 140 P. aeruginosa isolates highly resistant to ceftazidime.
During a 1-month period (June 2007), 85 hospital laboratories participating in the surveillance networks affiliated with ONERBA (Observatoire National de l'Epidémiologie de la Résistance Bactérienne aux Antibiotiques) collected nonredundant strains of P. aeruginosa resistant to ceftazidime (Caz r ) (as defined by the Comité de l'Antibiogramme de la Société Française de Microbiologie [CA-SFM] in 2006 [12]), except those obtained from screening samples and cystic fibrosis patients. The susceptibility tests were performed in each laboratory according to their routine testing methods. All isolates showing an inhibition zone of Ͻ15 mm around the ceftazidime-containing disk (30 g) or with a MIC of ceftazidime of Ͼ32 g/ml were sent to a central laboratory for further investigation. In addition, the total number of patients with at least one clinical specimen positive for P. aeruginosa as well as the number of hospitalization days was recorded in each partici-pating center during the study period. The central laboratory confirmed bacterial identification by using API32GN strips (bioMérieux, Craponnes, France) and determined the MICs of eight antipseudomonal antibiotics by the conventional 2-fold dilution method in agar (26) . The ␤-lactamase contents of the strains were first analyzed by isoelectric focusing (IEF) (23) and then confirmed by gene sequencing with consensus primers targeting the bla TEM , bla PSE , bla SHV , bla PER , bla VEB , bla GES , bla BEL , bla CTX-M, bla VIM , bla SPM , bla OXA-I group, bla OXA-II group, bla OXA-III group, and bla OXA-18 genes (1, 3, 5, 6, 24, 25, 28, 30-32, 35, 38) . Genes bla IMP , bla GIM , and bla OXA-9 , respectively, were also specifically amplified with primers IMP2004-A and IMP2004-B (5Ј-ACAYGGYTTGG TTGTTCTTG-3Ј and 5Ј-GGTTTAAYAAAACAACCACC-3Ј, respectively), GIM-A and GIM-B (5Ј-GGAGTATATCTT CATACCTCC-3Ј and 5Ј-TTCCAACTTTGCCATGCCCC-3Ј, respectively), and OXA9A and OXA9B (5Ј-CCGAGAGATC GCACATACAA-3Ј and 5Ј-CCCATCAACACGGGTAATT C-3Ј, respectively). Class 1 integrons were amplified in the isolates producing ESBLs, MBLs, and ES-OXAs with consensus primers (20) for content analysis and bla ESBL , bla MBL , and bla ES-OXA localization. Purified amplicons were sequenced on both strands, and their nucleotide sequences were compared and aligned with reference sequences using the NCBI BLAST program (2) . Clonality of the Caz r isolates was investigated by pulsed-field gel electrophoresis (PFGE) of DraI macrorestricted genomic DNA (36, 37) . Incidence of P. aeruginosa infections. Eighty-five hospital laboratories from 70 cities in France were enrolled in the study ( Fig. 1 ). With 58,022 beds, the participating hospitals accounted for a total annual activity of 17 million hospital days. The total catchment area population was 8 million people, which corresponds to 13% of the French population. Public (university-affiliated or general) hospitals accounted for 95% of the hospital beds. During the 1-month study, the participating centers isolated 2,326 nonredundant isolates of P. aerugi-nosa, giving an attack rate of 0.76 cases per 100 admissions or a global incidence of 1.58 per 1,000 patient days. One hundred forty of these isolates (6.0%) appeared to be resistant to ceftazidime (MIC of Ͼ32 g/ml). The resistance rates were similar between the university-affiliated (6.4%) and general (5.3%) hospitals, for a global incidence of Caz r P. aeruginosa isolates of 0.095 per 1,000 patient days.
Secondary ␤-lactamases in Caz r P. aeruginosa. The ␤-lactamases detected in the 140 Caz r isolates are indicated in Table  1 . Six ESBLs, four MBLs, and five ES-OXAs were identified in 13 isolates, for an overall prevalence of 9.3% of the 140 Caz r isolates and 0.6% of the total isolates. Table 2 gives the resistance levels to antipseudomonal compounds and characteristics of the isolates producing these enzymes.
In our series, the overall prevalence of P. aeruginosa strains producing ESBLs or MBLs remains relatively low, far below that observed in some Asian countries (4, 10), Latin America (9), or Turkey (27) but in concordance with those observed in previous studies in France (7, 8, 13, 15-17, 22, 29, 39) .
However, we showed here an unexpected proportion of P. aeruginosa strains producing ES-OXAs (OXA-19 and OXA-28). As expected, all of the bla ES-OXA genes were borne by class 1 integrons (Table 2) (33). Some new extended-spectrum oxacillinases have recently been described in several European countries (19, 33) . Altogether, these data suggest the possible emergence of this class of enzymes in P. aeruginosa. bla VIM and bla VEB genes are usually carried on class 1 integrons (34, 40) . However, bla VIM-2 , in isolates P19 and P22, and bla VEB-1 , in isolate P151, have not been associated with such genetic determinants.
Genotyping. One hundred thirty-seven isolates (3 isolates were nontypeable using PFGE) clustered in 113 PFGE patterns as follows: 98 unique patterns, 12 patterns including isolates from two patients, 1 pattern including isolates from 3 patients, 1 pattern including isolates from 4 patients, and 1 pattern including isolates from 8 patients. In most cases, the clonally related isolates were recovered from the same hospital -2a................................................................................................. -1.................................................................................................... 1  VEB-1a -2.................................................................................................... 1  IMP-18.................................................................................................. 1  OXA-30, PSE-1, VIM-2, PER-1 or from hospitals in the same region. Regarding the isolates producing ESBLs, MBLs, or ES-OXAs, genotypic analysis revealed that a clone (PFGE pattern A) producing OXA-19 had spread in two hospitals (Nancy and Epinal, France, 70 km apart). The spread of this clone has been described in a recent publication (11) . A second clone (PFGE pattern F), producing both PER-1 and VIM-2, was isolated in different wards of the same university hospital in Paris, France, while a third clone (PFGE pattern H), producing SHV-2a, was detected in two other hospitals in the north of France (Lille and Cambrai, 68 km apart) ( Fig. 1) .
Since most ES-OXAs are poorly inhibited by clavulanate, used in screening tests (14) , Pseudomonas aeruginosa strains expressing these enzymes remain difficult to recognize in routine testing and require genotypic methods. ES-OXAs have been described to occur sporadically, but their spread in the clinical setting remains poorly understood and probably underestimated. Our data stress the need for a simple and reliable routine test able to detect ESBLs, MBLs, and ES-OXAs produced by clinical P. aeruginosa strains. This test will be helpful to rapidly implement control measures for preventing the spread of multidrug-resistant strains harboring emerging resistance mechanisms. bla genes borne by class 1 integrons are indicated in boldface type. The gene cassettes and order for these isolates are as follows, with GenBank accession numbers given in parentheses: for P9, P11, and P122, aacA4 and bla OXA-19 (FJ906752); for P66, bla OXA-2 and bla OXA-19 ; for P174, aacA4 and bla OXA-28 (FJ374756); for P67, bla VIM-2 ; and for P85, dfrA22 and bla IMP-18 . b Tic, ticarcillin; Tzp, piperacillin-tazobactam; Caz, ceftazidime; Fep, cefepime; Atm, aztreonam; Ipm, imipenem; Amk, amikacin; Cip, ciprofloxacin. Drug susceptibility according to current NCCLS/CLSI breakpoints (26) is shown in boldface type: for Tic, MICs of Յ64 g/ml; for Tzp, MICs of Յ64 g/ml; for Caz, MICs of Յ8 g/ml; for Fep, MICs of Յ8 g/ml; for Atm, MICs of Յ8 g/ml; for Ipm, MICs of Յ4 g/ml; for Amk, MICs of Յ16 g/ml; and for Cip, MICs of Յ1 g/ml. The susceptible reference strain P. aeruginosa ATCC 27853 was used as the internal quality control. c MIC of piperacillin with a fixed concentration (4 g/ml) of tazobactam. d The pI value for IMP-18 has not been reported in the literature. IEF experiments for this isolate showed a smear between pI 5.0 and 7.5. e ETA, endotracheal aspiration.
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